Cash, cash equivalents and marketable securities were approximately $594.0M as of June 30, 2025. “In the first half of 2025, we reached key milestones that bring us closer to delivering on our mission,” said Kevin Koch, CEO. “With strong funding in place, we’re advancing our skeletal and cardiac muscle programs and building the commercial infrastructure with precision and purpose to support a potential U.S. launch of sevasemten in Becker. We’re also actively exploring Phase 3 trial designs in HCM and Duchenne, while continuing to advance our pipeline through bold, innovative R&D.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts
- Edgewise Therapeutics initiated with a Strong Buy at Raymond James
- Edgewise Therapeutics initiated with a Buy at H.C. Wainwright
- Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush